Payment overview · 2025
General Payments
$130.36
7 reported records · 6 companies
Healthcare provider profile · identity verified
James D Murphey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLEVELAND, GA · NPI 1740472208
Verified facts
What the public records show
CMS Open Payments records show James D Murphey, M.D. received $130.36 in general payments during 2025 across 7 reported records.
GlaxoSmithKline, LLC. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.83 | 26.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.88 | 18.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.98 | 16.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.98 | 14.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.48 | 12.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.21 | 11.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.36 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 476 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 139 |
| Omeprazole | Omeprazole | 384 | 110 |
| Lisinopril | Lisinopril | 360 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 89 |
| Gabapentin | Gabapentin | 337 | 99 |
| Losartan Potassium | Losartan Potassium | 315 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 299 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 65 |
| Metformin Hcl | Metformin Hcl | 230 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 56 |
| Alendronate Sodium | Alendronate Sodium | 203 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 62 |
| Tramadol Hcl | Tramadol Hcl | 186 | 47 |
| Sertraline Hcl | Sertraline Hcl | 185 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 47 |
| Simvastatin | Simvastatin | 153 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 48 |
| Allopurinol | Allopurinol | 133 | 39 |
| Ozempic | Semaglutide | 132 | 29 |
| Trazodone Hcl | Trazodone Hcl | 122 | 37 |
| Ezetimibe | Ezetimibe | 121 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 43 |
| Potassium Chloride | Potassium Chloride | 108 | 33 |
| Famotidine | Famotidine | 107 | 30 |
| Montelukast Sodium | Montelukast Sodium | 105 | 31 |
| Prednisone | Prednisone | 105 | 66 |
| Carvedilol | Carvedilol | 102 | 31 |
| Buspirone Hcl | Buspirone Hcl | 101 | 28 |
| Meloxicam | Meloxicam | 97 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 34 |
| Metformin Hcl Er | Metformin Hcl | 88 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 21 |
| Finasteride | Finasteride | 87 | 23 |
| Jardiance | Empagliflozin | 83 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 36 |
| Glimepiride | Glimepiride | 78 | 24 |
| Eliquis | Apixaban | 77 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 22 |
| Spironolactone | Spironolactone | 67 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 17 |
| Bupropion Xl | Bupropion Hcl | 59 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 14 |
| Furosemide | Furosemide | 56 | 20 |
| Torsemide | Torsemide | 55 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Trulicity | Dulaglutide | 52 | 15 |
| Benazepril Hcl | Benazepril Hcl | 50 | 15 |
| Estradiol | Estradiol | 50 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 15 |
| Farxiga | Dapagliflozin Propanediol | 47 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Glipizide | Glipizide | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 12 |
| Celecoxib | Celecoxib | 43 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Topiramate | Topiramate | 37 | 11 |
| Ondansetron Odt | Ondansetron | 36 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Fluconazole | Fluconazole | 31 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 20 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Colchicine | Colchicine | 24 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Prolia | Denosumab | 18 | 13 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Diclofenac Epolamine | Diclofenac Epolamine | 17 | suppressed |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Clonidine | Clonidine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.36 · 7 records | GlaxoSmithKline, LLC. | BREZTRI, FREESTYLE LIBRE 3, INSPIRE, NURTEC ODT, TRELEGY ELLIPTA, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error